TGen to Participate in DoD Program Studying Pharmacogenomics of Breast Cancer | GenomeWeb
NEW YORK (GenomeWeb News) – The Translational Genomics Reserach Institute will play a "primary" role in a $10.7-million Department of Defense breast cancer research program, the nonprofit said yesterday.
 
The multi-institutional, five-year research program is led by Philadelphia’s Fox Chase Cancer Center. The grant focuses on developing a new treatment model for breast cancer to reverse resistance to anti-estrogen therapy.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.